ABT vs PHG: Abbott Laboratories and Koninklijke Philips NV ADR compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Abbott Laboratories is the larger company, worth $174.8B, about 7.5 times Koninklijke Philips NV ADR.
- Abbott Laboratories grew revenue faster over the last year (+7.8% vs -1.0%).
- Abbott Laboratories keeps more of each dollar of revenue as operating profit (17.1% vs 8.0%).
- On earnings, Koninklijke Philips NV ADR is the cheaper stock (21.2x vs 28.1x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | ABT | PHG |
|---|---|---|
| Market cap | $174.8B | $23.5B |
| Share price | $99.60 | $24.24 |
| Revenue (last fiscal year) | $44.3B | $17.8B |
| Free cash flow (last fiscal year) | $7.4B | — |
| Revenue growth, last year | +7.8% | -1.0% |
| Revenue growth per year, last 5 fiscal years | +0.7% | +1.0% |
| Operating margin | 17.1% | 8.0% |
| Net margin | 13.9% | 5.0% |
| Return on equity | 12.1% | 8.2% |
| P/E (trailing) | 28.1x | 21.2x |
| Price / free cash flow | 23.6x | 26.3x |
| EV / EBITDA | 17.0x | 9.83x |
| FCF growth the price implies | 7.2% | — |
| Dividend yield | 2.4% | 4.1% |
| Debt / equity | 1.11x | 1.46x |
| Fundamental grade | C | D |
| Superinvestors holding it | 11 | 3 |
| Insider purchases, last 12 months | 10 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Abbott Laboratories
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $43.1B | $8.6B | 19.6% |
| 2022 | $43.7B | $7.8B | 19.2% |
| 2023 | $40.1B | $5.1B | 16.2% |
| 2024 | $42.0B | $6.4B | 16.3% |
| 2025 | $44.3B | $7.4B | 18.2% |
Koninklijke Philips NV ADR
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $17.2B | — | 3.2% |
| 2022 | $17.8B | — | -8.6% |
| 2023 | $18.2B | — | -0.63% |
| 2024 | $18.0B | — | 2.9% |
| 2025 | $17.8B | — | 8.0% |
Where the revenue comes from
Abbott Laboratories · by segments, 2025
Medical Devices$21.4B48%
Diagnostics$8.9B20%
Nutritionals$8.5B19%
Established Pharmaceuticals$5.5B12%
Koninklijke Philips NV ADR · by segments, 2025
Diagnosis & Treatment$8.5B48%
Connected Care$5.1B28%
Personal Health$3.7B21%
Other$554M3%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open ABT in InvestinglyQuestions
Which is bigger, Abbott Laboratories or Koninklijke Philips NV ADR?
Abbott Laboratories (ABT), at $174.8B against $23.5B.
Is ABT or PHG cheaper?
By trailing P/E, Koninklijke Philips NV ADR (21.2x) is cheaper than Abbott Laboratories (28.1x). A lower multiple can also mean the market expects less growth.
Which grows faster, ABT or PHG?
Abbott Laboratories: revenue grew +7.8% over the last year, against -1.0%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.